SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is currently a major focus of community debate, with bulls citing its long-term ecosystem evolution and utility as reasons for optimism, while skeptics dismiss it as a stagnant project due to its massive circulating supply. The discourse is heavily fueled by competing narratives between investors advocating for its potential future burns and those urging others to rotate into alternative tokens or Bitcoin.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing significant downward pressure as the community expresses frustration over its persistent decline, with many debating whether current price levels represent a historical accumulation opportunity or a value trap. Investors are closely monitoring its performance relative to other major assets while discussing concerns regarding tokenomics, broader market volatility, and the lack of a clear bullish catalyst to reverse the current trend.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is experiencing heightened investor activity and positive momentum following a landmark agreement with the U.S. administration to lower drug prices in exchange for a significant tariff exemption and domestic manufacturing investments. The community is also reacting to strong pipeline updates, including promising Phase III results for baxdrostat and the transition of its listing to the NYSE, which have reinforced analyst confidence in the company's long-term revenue targets.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is trending as investors digest the implications of recent pipeline expansions and the impact of the upcoming Q2 earnings report on July 30, with active community discussion focusing on whether these moves signal a long-term growth strategy or a potential M&A event. Despite ongoing buyout speculation involving big pharma suitors, market participants remain focused on commercial momentum for Rezdiffra and the company's ability to maintain its leadership position in the MASH treatment sector.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is trending as investors digest significant strategic shifts, including a major $10.9 billion acquisition of Apogee Therapeutics to bolster its immunology pipeline and ongoing discussions regarding its competitive positioning in oncology and obesity markets. Community sentiment is mixed, with long-term shareholders focused on dividend stability and portfolio expansion, while others debate whether the stock is undervalued given recent pipeline updates and competitive pressure in its key immunology franchises.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing heightened trading volume and social activity as investors debate the impact of the JasmyChain L2 launch and potential Japanese regulatory tailwinds on its data-utility model. While long-term supporters continue to dollar-cost average, emphasizing ecosystem growth, critics remain skeptical, pointing to the project's historical volatility and recent performance relative to newer tokens within the same ecosystem.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

The Technology Select Sector SPDR Fund (XLK) is currently navigating a period of heightened scrutiny as investors shift focus from pure AI spending to demand for tangible revenue and margin growth. Community discourse is centered on the risks of elevated valuations and institutional rotation toward other sectors, making the performance of mega-cap holdings like NVDA, AAPL, and MSFT the primary driver of the ETF's near-term direction.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express is facing significant volatility following potential regulatory discussions regarding interest rate caps, driving heavy debate among traders about the long-term impact on its premium business model. While some investors remain cautious about potential legislative headwinds, the community is actively tracking the stock's support levels and comparing its resilience against other payment networks and card issuers.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending amid heightened community anticipation surrounding the potential passage of the Clarity Act and legislative developments in global markets like Russia. Investors are actively debating whether these regulatory shifts will serve as a definitive catalyst for institutional utility or if price action remains constrained by ongoing market volatility and dilution concerns.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is seeing heightened community discussion as investors weigh the stock's significant pullback against its improving fundamentals and the anticipated launch of VEPPANU. While some shareholders express frustration over recent price volatility and lack of management communication, many remain bullish, pointing to a potential short squeeze driven by the company's profitability, growth in its product portfolio, and high short interest that keeps days to cover elevated.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PLTR Burry is trying to cause algos to sell-off based on keywords. He tried same BS in one of his last attempts advocating accounting trickery with the Karp private jet cost crap. Algo sees accounting fraud headline and sells off. It&#39;s all BS.   
  
Anthropic isn&#39;t eating into PLTR, PLTR and anthropic are eating into the human inefficiency and generic softwares. Enterprises will gladly spend 200M a year on tech to eliminate 1B in people costs or 500m in superfluous tech spend. His argument is idiotic, but then again he isn&#39;t really trying to debate; he is trying to cause a sell-off

HITHERE

Grinch

D Winner

Jordan Belfort

bulld0zer's new account

J Hardy

Alivia

Vincent Spirite

Yasu Kanada

Rick

Carson

John Doe

Edward Fresa

StockTwits Web

Palantir Technologies Inc

 Burry is trying to cause algos to sell-off based on keywords. He tried same BS in one of his last attempts advocating accounting trickery with the Karp private jet cost crap. Algo sees accounting fraud headline and sells off. It's all BS.   
  
Anthropic isn't eating into PLTR, PLTR and anthropic are eating into the human inefficiency and generic softwares. Enterprises will gladly spend 200M a year on tech to eliminate 1B in people costs or 500m in superfluous tech spend. His argument is idiotic, but then again he isn't really trying to debate; he is trying to cause a sell-off

niksIndian

Arcides M.

@PeteZah1 algos only work for one pump or drop, doesn&#39;t last all day.

 algos only work for one pump or drop, doesn't last all day.

AG5000

@PeteZah1 
If the SEC is going to allow algorithms to dominate intraday trading, then it should put a stop to tactics like this.

StockTwits for iOS

 
If the SEC is going to allow algorithms to dominate intraday trading, then it should put a stop to tactics like this.

@PeteZah1 But it’s a fact. Anthropic is coming in strong

 But it’s a fact. Anthropic is coming in strong

@Arcides no but as someone who has been in the market for a long time, he clearly understands they are built to identify negative headlines. He is gaming the system clearly

 no but as someone who has been in the market for a long time, he clearly understands they are built to identify negative headlines. He is gaming the system clearly

@niksIndian but their success as an llm doesn&#39;t indicate palantir is failing or will fail or even lose marketshare. My org spends on llms, but also spends tons on other software that won&#39;t be replaced by llms, some may be.  
 
The point is both are eating into jobs/salaries more than they are competing with each other. Enterprises will fire 10k people and utilize both

 but their success as an llm doesn't indicate palantir is failing or will fail or even lose marketshare. My org spends on llms, but also spends tons on other software that won't be replaced by llms, some may be.  
 
The point is both are eating into jobs/salaries more than they are competing with each other. Enterprises will fire 10k people and utilize both

@PeteZah1 agreed! As a dev myself, more than half of saas products are being replaced by internal tooling built using LLMs.

Richard Royce

 agreed! As a dev myself, more than half of saas products are being replaced by internal tooling built using LLMs.

@PeteZah1 looks like it worked like a charm